MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 11:48:59 24/05/2024 pm IST | ||
| 4.06 EUR | -5.36% |
|
| Current month | -12.88% | ||
| 1 month | -13.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 4.06 | -5.36% |
| 23/24/23 | 4.29 | -3.16% |
| 22/24/22 | 4.43 | +3.75% |
| 21/24/21 | 4.27 | +1.91% |
| 20/24/20 | 4.19 | -0.95% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 11:48 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME4D4D |
| ISIN | DE000ME4D4D0 |
| Date issued | 29/11/2023 |
| Strike | 276.6 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.75 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.57 € |
|---|---|
| Lowest since issue | 0.71 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
586.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+33.94%
- Stock Market
- Certificates
- Certificat
